A pooled analysis of the AMY2009 and AMY3001 trials showed daratumumab plus VCd yielded hematologic complete responses in cardiac-involved AL amyloidosis.
|Videos|April 18, 2018
Blood-Tumor Barrier’s Role in Brain Mets
Author(s)Patricia S. Steeg, PhD
In this video, Dr. Patricia Steeg discusses the role of the blood-tumor barrier in both development and treatment of brain metastases.
Advertisement
In this video, Dr. Patricia Steeg discusses the role of the blood-tumor barrier in both development and treatment of brain metastases.
Advertisement
Related to this article
David R. Gandara, MD, discusses how EMPOWER-Lung 1’s findings in KRAS G12C-mutated disease should inform the design of combination trials.
Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.
Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.
In the LINKER-SMM1 trial, single-agent linvoseltamab produced a 100% overall response rate among evaluable patients with high-risk smoldering multiple myeloma.
David R. Gandara, MD, explains what makes KRAS G12C biologically distinct from other KRAS subtypes in NSCLC immunotherapy response.
Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA MCGP Panel Votes in Favor of the Galleri Multicancer Early Detection Test
2
Approaching Cardiovascular Risk in Prostate Cancer Hormonal Therapy
3
FDA Grants Approval to Lirafugratinib for Advanced Cholangiocarcinoma with FGFR2 Alteration
4
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
5